Prospective Evaluation of Artificial Intelligence R&D tool for patient stratification in Pancreatic and Liver cancers (PEAR-PAL)

人工智能R的前瞻性评估

• 批准号: 10036967
• 金额: $ 26.16万
• 依托单位: OUROTECH LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10036967
• 关键词: Prospective; Evaluation; Artificial; Intelligence; R&D

Hepatocellular carcinoma (HCC) and pancreatic ductal adenocarcinoma (PDAC) are two of the most challenging gastrointestinal diseases to treat. HCC and PDAC have the worst outcome of all liver and pancreatic cancers respectively, with over 80% and 95% 2-year recurrence (cancer coming back) after surgery, owing to a lack of efficient, targeted treatments and means of matching patients with the correct stream of treatment.Pear Bio have developed an organ-on-a-chip technology and computer vision pipeline through which various therapeutic regimens can be tested simultaneously on patient tumours. This technology consists of a micro-scale system used for mimicking human tumours and model cancer behaviour in the lab (organ-on-a-chip), combining the use of human cancer cells, hydrogels, microfluidics and image analysis. With this, Pear Bio is able to test different treatments on a patient's own tumour, outside of their body, predicting which one is going to be more beneficial for that specific patient, and which ones are ineffective. This innovative technology represents a breakthrough in personalised cancer care, helping oncologists avoid treatments that provide patients with no benefit, thus minimising unnecessary side effects, improving patient outcomes and likelihood of survival, and saving the NHS critical resources and expenditure.With PEAR-PAL, Pear Bio aims to expand the tool's clinical utility to high unmet need cancers, namely advanced pancreatic and liver. We will be collaborating with King's College Hospital in order to source fresh PDAC and HCC patient samples. Samples will be cultured in Pear Bio's proprietary organ-on-a-chip technology and tested against various treatment regimes in the Pear Bio test (5 days). Multiple metrics are measured and visualised, including cell viability, the shrinking/growth of the tumour, cell migration and speed. This data is compiled into a report that will allow an oncologist to weigh treatment options and proceed with an effective treatment. Collaboration with London IVD will enable a comprehensive assessment of Pear Bio's test route to market, commercialisation strategy, health economics as well as patient and public engagement.As this study is non-interventional, patient safety, health or choice of treatment will not be affected. At the conclusion of this project, further collaborations will be used to run clinical trials for regulatory approval of the diagnostic test in pancreatic and liver cancers. In future studies, Pear Bio's test will be run prior to the start of therapy as a treatment selection tool, aiming to guide oncologists in their choice of regimen for any given patient.

肝细胞癌（HCC）和胰腺导管腺癌（PDAC）是两种最具挑战性的胃肠道疾病，分别是所有肝癌和胰腺癌中预后最差的两种，2年复发率分别超过80%和95%（癌症复发）手术后，由于缺乏有效的，Pear Bio开发了一种器官芯片技术和计算机视觉管道，通过该技术可以同时对患者肿瘤进行各种治疗方案的测试。该技术包括一个微型系统，用于模拟人类肿瘤和在实验室中模拟癌症行为（器官芯片），结合使用人类癌细胞，水凝胶，微流体和图像分析。有了这个，Pear Bio能够在患者自己的肿瘤上测试不同的治疗方法，预测哪种治疗方法对特定患者更有益，哪些治疗方法无效。这一创新技术代表了个性化癌症护理的突破，帮助肿瘤学家避免对患者没有好处的治疗，从而最大限度地减少不必要的副作用，改善患者的预后和生存可能性，并节省NHS的关键资源和支出。Pear Bio旨在通过PEAR-PAL将该工具的临床实用性扩展到高未满足需求的癌症，即晚期胰腺癌和肝癌。我们将与国王学院医院合作，以获取新鲜的PDAC和HCC患者样本。样本将在Pear Bio专有的器官芯片技术中培养，并在Pear Bio测试中针对各种处理方案进行测试（5天）。测量和可视化多个指标，包括细胞活力，肿瘤的缩小/生长，细胞迁移和速度。这些数据被汇编成一份报告，将允许肿瘤学家权衡治疗方案，并继续进行有效的治疗。与伦敦IVD的合作将使我们能够全面评估Pear Bio的市场测试路线、商业化战略、卫生经济学以及患者和公众参与。由于这项研究是非干预性的，因此患者的安全、健康或治疗选择不会受到影响。在该项目结束时，进一步的合作将用于运行临床试验，以获得胰腺癌和肝癌诊断测试的监管批准。在未来的研究中，Pear Bio的测试将在治疗开始之前运行，作为治疗选择工具，旨在指导肿瘤学家为任何特定患者选择治疗方案。